This article has been updated to include a response from Med BioGene.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Signal Genetics has made what it said is a "superior offer" to license Med BioGene's LungExpress Dx technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.